Freeman Spogli Institute for International Studies Program on Energy and Sustainable Development Stanford University


News and commentary


Photo of Alan Garber

Alan M. Garber, MD, PhD

Provost of Harvard University, Mallinckrodt Professor of Health Care Policy at Harvard Medical School and a Professor of Economics in the Harvard Kennedy School of Government and the Faculty of Arts and Sciences and Former CHP/PCOR Director; Henry J. Kaiser, Jr. Professor Emeritus

View Alan Garber's bio, list of research, recent publications and events »


Display news from   or latest news


No news articles about Alan Garber found in July, 2013



« News from July 2011



Select news articles from:
«

July 2013

»

S

M

T

W

T

F

S

 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

   

News around the web

Individualized cost-effectiveness analysis useful for clinicians and patients
John Ioannidis and Alan Garber from Stanford University, USA, discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients. The authors say that "Cost-effectiveness analysis offers a foundation for rational decision-making and can be very helpful in making health care more efficient and effective at the population level.
July 12, 2011 in EurekAlert (press release)

Stanford's Garber assumes role of Harvard provost
Professor of Medicine Alan Garber MD '83 will sport crimson rather than cardinal this fall as he takes on the role of provost at Harvard University in Cambridge, Mass. In his 25 years at Stanford, Garber has distinguished himself beyond the medical ...
April 18, 2011 in The Stanford Daily

Harvard Names Alan Garber of Stanford as Its Next Provost
Harvard University named Alan Garber, a Stanford University professor of medicine and economics, as its next provost, replacing Steven Hyman, who will step down at the end of the academic year.
April 15, 2011 in Bloomberg

Cancer-vaccine review highlights debate over costs and benefits of pricey ...
(The drug, which was developed at Stanford, was the first-ever cancer vaccine to get the FDA's nod.) Now, the federal government has launched what is being ...
November 8, 2010 in Scope (blog)

New drug may provide more cost-effective stroke prevention than warfarin ...
STANFORD, Calif. — A newly approved drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm — and may also offer ...
November 1, 2010 in EurekAlert (press release)

More news around the web »